Skip to main
  1. Stocks
  2. Sarepta Therapeutics
  3. Forecast
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 20%

Bulls say

Sarepta Therapeutics is viewed positively because its core PMO franchise remains resilient, with 3Q PMO product revenue of $240.3M beating expectations and helping support cash flow, while total net product revenue guidance was narrowed to $1.25B-$1.3B on improved underlying performance. The Elevidys story also remains constructive, as 3Q U.S. revenue of $83.5M met Street expectations and interim ENDURE data showed no cases of ALI among 11 patients on prophylactic sirolimus, while exploratory PRO data suggested better mobility preservation versus external controls. In addition, lower-than-expected R&D spend at $82M, manageable SG&A of $118M, and the $39M patent settlement reduce operational and legal uncertainty, even as competition and regulatory review remain key watch items.

Bears say

Sarepta Therapeutics is facing a fragile fundamentals story because Elevidys sales of $83.5M in 3Q aligned with a “downquarter” but still suggest a predictable, and potentially flat, trajectory rather than the inflection needed to reaccelerate growth. The write-up highlights unresolved efficacy questions from non-significant randomized NSAA results, weaker-than-expected external-control support, and a sub-$400M peak opportunity by ’28, while safety concerns remain material with 7-9% serious ALI rates and prior fatal liver failure in non-ambulatory patients. With the PMO franchise also exposed to regulatory, clinical, and competitive risk, the company may struggle to generate enough durable cash flow to meet debt and partnership obligations.

Sarepta Therapeutics (SRPT) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction

Get the latest Sarepta Therapeutics (SRPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Sarepta Therapeutics (SRPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 10 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction

Get the latest Sarepta Therapeutics (SRPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Sarepta Therapeutics (SRPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SRPT stock data and trends